Ivermectin 1% cream is FDA-approved for the inflammatory lesions of rosacea — the papules and pustules that characterise papulopustular rosacea. Unlike the oral tablets, this is a topical formulation applied directly to the face, and it is one of the better-supported treatments in dermatology, with head-to-head trial data behind it.
Ivermectin appears to act on rosacea through two mechanisms at once. The first is antiparasitic: Demodex folliculorum mites live in facial hair follicles and are found at substantially higher densities in rosacea patients than in unaffected skin. Ivermectin kills them.
The second is anti-inflammatory, and it may matter more. Ivermectin downregulates inflammatory mediators including cathelicidin LL-37 and reduces neutrophil-driven inflammation independently of its effect on mites. This dual action is the likely explanation for its performance against comparators that only address inflammation.
In two large pivotal randomised trials, ivermectin 1% cream applied once daily produced significantly greater reductions in inflammatory lesion counts than vehicle over 12 weeks, with a substantially higher proportion of patients rated clear or almost clear.
In a head-to-head trial against metronidazole 0.75% cream — long a standard topical for rosacea — ivermectin 1% once daily outperformed metronidazole twice daily on lesion count reduction and on patient-reported outcomes. An extension study also found longer remission before relapse in the ivermectin group.
A pea-sized amount is applied once daily to the entire face, avoiding eyes and lips. Improvement is usually visible within four weeks and continues over 12 weeks and beyond. Transient stinging, dryness or a brief flare in the first weeks is common and typically settles.
Rosacea is a chronic condition. Ivermectin cream controls it rather than cures it, and lesions generally return over months if treatment stops.
GMP-certified human formulations — tablets and 1% cream. Never veterinary products. Most USA orders ship within 1–7 business days.
View products and pricingYes. Topical ivermectin 1% cream is FDA-approved for the inflammatory lesions of rosacea. This is a separate approval from the oral tablets, which are approved for strongyloidiasis and onchocerciasis.
In a direct head-to-head randomised trial, ivermectin 1% once daily reduced inflammatory lesions more than metronidazole 0.75% twice daily, and an extension study found longer remission before relapse.
Most people see improvement within about four weeks, with continued benefit through 12 weeks. A brief worsening in the first week or two is common and usually settles.
No. Rosacea is a chronic condition and ivermectin cream controls the inflammatory lesions rather than curing the underlying tendency. Lesions typically return over months if treatment is stopped.